Clinical Trial

Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers

Study acronym: RADIO-PBM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this feasibility, prospective, single-center trial is to compare an intra-oral Photobiomodulation (PBM) via the Caremin650TM device (NeoMedLight) and a transcutaneous PBM via the ATP 38® device (Swiss Bio Innov) in patients treated with radiotherapy or chemoradiotherapy for cancer of the oropharynx or oral cavity. PBM session will be carried out first at the rate of two sessions per week for preventive purposes, and then, in case of occurence of grade 1 mucositis, three sessions per week with curative purpose.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-10.
Trial Details
NCT Number NCT06458517
Lead Sponsor Centre Paul Strauss
Conditions Head and Neck Neoplasms
Enrollment 60 participants
Start Date 2026-06-15
Primary Completion 2029-11-15 (estimated)
Study Completion 2029-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-05